---
title: "BCL2"
date: 2023-05-10 00:00:00
layout: post
categories: Gene
summary: "# Analysis of Gene BCL2"
tags: ['BCL2', 'Apoptosis', 'Cancer', 'ChemotherapyResistance', 'TargetedTherapy', 'Venetoclax', 'Prognosis', 'Mutation']
---

# Analysis of Gene BCL2

## Gene Information
The BCL2 (B-cell lymphoma 2) gene is located on chromosome 18q21.33 and consists of 5 exons. The gene encodes a protein of 26 kDa, which regulates apoptosis and inhibits cell death. The gene has been associated with several diseases including cancer.

## Function
The BCL2 protein functions in the regulation of programmed cell death, also known as apoptosis. It is involved in the inhibition of the intrinsic pathway of apoptosis, preventing cells from undergoing cell death. The overexpression of BCL2 protein can lead to the survival of cancer cells and resistance to chemotherapy.

## External IDs and Aliases
- HGNC: 990
- Ensembl: ENSG00000171791
- NCBI Entrez: 596
- OMIM: 151430
- UniProtKB/Swiss-Prot: P10415
- Aliases: BCL2L, Bcl-2, PPP1R50

## AA Mutation List and Mutation Type with dbSNP ID
- c.290C>T (p.Pro97Leu) rs1801018
- c.109G>A (p.Arg37Gln) rs1801019
- c.594-26G>A rs562962037
- c.271G>A (p.Ala91Thr) rs1057131

## Somatic SNVs/InDels with dbSNP ID
- c.163C>A (p.Thr55Asn) rs80371463
- c.404T>C (p.Met135Thr) rs77876063
- c.458G>A (p.Ala153Thr) rs551774458

## Related Disease
The BCL2 gene has been associated with various types of cancer, including lymphoma, leukemia, breast cancer, and lung cancer.

## Treatment and Prognosis
The overexpression of BCL2 protein is associated with resistance to chemotherapy and poor prognosis in cancer patients. Targeted therapy such as BCL2 inhibitors are currently being developed as a potential treatment for cancers with BCL2 overexpression.

## Drug Response
The BCL2 inhibitor venetoclax has been approved for the treatment of chronic lymphocytic leukemia (CLL) with a specific chromosomal abnormality that results in high BCL2 levels.

## Related Papers
- Subject: BCL2 and cancer
- Author: Reed JC
- DOI: 10.1038/nrg3585

- Subject: Venetoclax for chronic lymphocytic leukemia
- Author: Seymour JF
- DOI: 10.1056/NEJMoa1513257

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**